摘要
目的:检测非小细胞肺癌中EGFR基因扩增、点突变及蛋白的表达情况,为探讨EGFR在非小细胞肺癌的发生、发展中的作用以及化疗方式的选择上提供信息。方法:应用FISH和Q-PCR方法检测EGFR基因扩增和突变,应用免疫组织化学方法检测EGFR蛋白的表达情况,依据Robert免疫组化分级评分方法,把NSCLC的EGFR免疫组化与基因扩增和点突变检测进行比较及分析。结果:EGFR蛋白在非小细胞肺癌组织表达率为43.9%(36/82),FISH法检测EGFR基因扩增率为18.3%(15/82),Q-PCR法检测EGFR基因突变率为22.0%(18/82)。EGFR的表达与其基因扩增率正相关(P<0.05);其表达与其基因突变率不相关(P>0.05)。结论:EGFR免疫组化表达率高于FISH法检测基因扩增率及Q-PCR法检测突变率,但其无法替代分子生物学检测方法,三种方法结果互相结合,能更好的指导临床治疗方案的选择。
Objective：To compared immunohistochemistry with FISH and Q-PCR of EGFR express for providing information of EGFR in the occurrence and development of NSCLC,and the choice of chemotherapy.Methods：Writer used FISH and Q-PCR to detect EGFR gene amplification and mutations,using immunohistochemistry to detect expression of EGFR protein.According to Robert’s immunohistochemistry of grading standard,we compared these results of three methods.Results：The expression rates of the EGFR protein was 43.9%（36/82）.The amplification rate of EGFR gene was 18.3%（15/82）.The mutations rate of EGFR gene was 22.0%（18/82）.EGFR protein expression levels were associated with amplification of EGFR gene（P〈0.05）.Conclusion：The expression rates of the EGFR protein was significantly higher than the other two molecular biology methods.Combine immunohistochemistry with FISH and Q-PCR can help for choose better individualized chemotherapy and prediction of efficacy chemotherapy.
出处
《中外医学研究》
2012年第24期3-4,共2页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
非小细胞肺癌
表皮生长因子受体
免疫组化
荧光原位杂交法
实时荧光定量法
Non small-cell lung cancer
Epidermal growth factor receptor
Immunohistochemistry
Fluorescence in situ hybridization
Quantitative polymerase chain reaction
